|
May 15
|
BioSyent Releases Financial Results for First Quarter 2025
|
|
May 15
|
BioSyent Declares Second Quarter 2025 Dividend
|
|
May 15
|
Here's Why We Think BioSyent (CVE:RX) Is Well Worth Watching
|
|
May 8
|
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
|
|
Apr 30
|
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
|
|
Mar 15
|
BioSyent Full Year 2024 Earnings: Misses Expectations
|
|
Mar 13
|
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
|
|
Jul 24
|
FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.
|
|
Feb 6
|
BioSyent Declares First Quarter 2024 Dividend
|
|
Aug 8
|
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
|
|
Jul 6
|
BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
|